1095006-07-7

Upstream product

• 1095006-05-5 3-fluoro-5-[3-[[1-(2-hydroxyphenyl)cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-4-methyl-benzoic acid, methyl ester 
• 1068-55-9 isopropylmagnesium chloride 
• 765-30-0 Cyclopropylamine 
• 74511-44-7 o-(benzyloxy)benzonitrile 
• 103877-61-8 2-chloro-5-fluoro-4-methyl-benzoic acid 
• 103877-62-9 2-chloro-5-fluoro-4-methyl-3-nitro-benzoic acid 
• 1095005-79-0 1-(2-(benzyloxy)phenyl)cyclopropanamine 
• 1095005-98-3 2-chloro-5-fluoro-4-methyl-benzoic acid methyl ester 
• 201849-17-4 1-bromo-2-chloro-5-fluoro-4-methylbenzene 
• 1232287-16-9 methyl 3-amino-5-fluoro-4-methylbenzoate sulfuric acid salt 
• 1095006-03-3 3-[5-bromo-2-oxo-3-[[1-[2-(phenylmethoxy)phenyl]cyclopropyl]amino]-1(2H)-pyrazinyl]-5-fluoro-4-methyl-benzoic acid, methyl ester 
• 1095006-01-1 3-(3,5-dibromo-2-oxo-2H-pyrazin-1-yl)-5-fluoro-4-methyl-benzoic acid, methyl ester 
• 1095006-00-0 3-[(cyanomethyl)amino]-5-fluoro-4-methyl-benzoic acid, methyl ester 
• 1093087-06-9 3-amino-5-fluoro-4-methyl-benzoic acid methyl ester 

Downstream Products

• 1095006-08-8 3-[3-[[1-[2-(2-chloroethoxy)phenyl]cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-N-cyclopropyl-5-fluoro-4-methyl-benzamide 
• 1095004-78-6 N-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide 
• 1095004-79-7 N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2-[(2-hydroxyethyl)amino]ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-4-methyl-benzamide 

Relevant academic research and scientific papers

Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient

The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclopropyl-3-fluoro-4-methyl-5[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-benzamide or a salt thereo

PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES

The present invention relates to py razinone derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.